Responses with crizotinib in MET-amplified lung cancer show new targetable form of disease
A study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2014 reports the results of a first-in-human, phase 1 dose escalation trial of crizotinib (XALKORI) in 14 patients with advanced, MET-amplified ...
May 31, 2014
0
0